New drug cocktail aims to outsmart relapsed leukemia
NCT ID NCT03874052
First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times
Summary
This early-phase trial is testing whether adding ruxolitinib to the standard drugs azacitidine and venetoclax is safe for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. About 51 adults will receive the three-drug combination to find the best dose and check for side effects. The goal is to see if this approach can help control the disease better than current options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ruxolitinib, azacitidine, and venetoclax
- What this could lead to
- If it works, this could offer a new treatment option for patients with AML that has returned or not responded to prior therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 51 participants, so the main goal is safety, not proof of effectiveness. The combination may cause significant side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
OHSU Knight Cancer Institute
RECRUITINGPortland, Oregon, 97239, United States
-
Ohio State University Comprehensive Cancer Center
SUSPENDEDColumbus, Ohio, 43210, United States
-
UT Southwestern/Simmons Cancer Center-Dallas
SUSPENDEDDallas, Texas, 75390, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a targeted drug keep AML in check?
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Experimental combo for resistant leukemia shows early promise but trial halted
- Selective immune cell removal may tame transplant complications